​​Bentley and Terumo Aortic announce collaboration on groundbreaking clinical study advancing FEVAR procedures through the implantation of Terumo Aortic’s Fenestrated TREO® device and Bentley’s BeFlared FEVAR bridging stent​

Through this collaboration, Bentley and Terumo Aortic aim to bring their innovative solutions to benefit US patients suffering from complex abdominal aortic aneurysms, namely juxtarenal and suprarenal aneurysms. Following the completion of the joint clinical study and FDA approval, both companies plan to independently market their products in the US.  

BeFlared is the world’s first bridging stent specifically developed for FEVAR procedures. The stent is crimped on a specially designed stepped balloon which will reduce the number of steps that are needed for optimal deployment. Additionally, a third radiopaque marker aids in optimal positioning of the stents in the fenestration. Having already received CE certification from TÜV Süd, BeFlared is now available in most key markets. The “first in human” procedure was performed by Professor Stéphan Haulon in Paris in November 2024. 

Erik Pomp, CEO of Terumo Aortic commented: “Bentley’s BeFlared, the world’s first-to-market dedicated bridging stent, is a great fit for our Fenestrated TREO® platform. With its innovative features, this stent has the potential to become the gold standard in FEVAR procedures, thus complementing our Fenestrated TREO® platform”. 

“By partnering with Terumo Aortic, we’re advancing BeFlared’s role as the go-to bridging stent for FEVAR. Already available in most key markets, its value is being demonstrated through strong outcomes led by KOLs. This study will further solidify its impact in treating complex aortic aneurysms. Terumo Aortic’s Fenestrated TREO® platform is an excellent complement, and together, we are setting new standards in patient care” said Sebastian Büchert, CEO of Bentley. 

Terumo Aortic’s Fenestrated TREO® device offers a patient-specific solution tailored to the anatomical conditions and clinical needs for treating aortic aneurysms. To ensure perfusion of vital organs, the Fenestrated TREO® device can be designed to include up to five fenestrations, requiring reliable bridging stents to maintain perfusion to the target vessels.  

The combination of Fenestrated TREO® and BeFlared is designed to set a new benchmark for FEVAR procedures by offering both ease of use and reduced complications for patients. Together, Bentley and Terumo Aortic are driving innovation in the field of aortic disease treatment.